1. Home
  2. SUNS vs SCYX Comparison

SUNS vs SCYX Comparison

Compare SUNS & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sunrise Realty Trust Inc.

SUNS

Sunrise Realty Trust Inc.

HOLD

Current Price

$7.39

Market Cap

108.7M

Sector

Real Estate

ML Signal

HOLD

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

N/A

Current Price

$4.48

Market Cap

51.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SUNS
SCYX
Founded
2023
1999
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
108.7M
51.4M
IPO Year
2024
2014

Fundamental Metrics

Financial Performance
Metric
SUNS
SCYX
Price
$7.39
$4.48
Analyst Decision
Hold
Strong Buy
Analyst Count
1
1
Target Price
$8.75
$3.00
AVG Volume (30 Days)
49.6K
64.8K
Earning Date
05-14-2026
05-06-2026
Dividend Yield
16.17%
N/A
EPS Growth
N/A
61.36
EPS
0.54
N/A
Revenue
$21,571,434.00
$257,000.00
Revenue This Year
$70.81
N/A
Revenue Next Year
N/A
$608.78
P/E Ratio
$13.46
N/A
Revenue Growth
102.96
N/A
52 Week Low
$7.24
$0.57
52 Week High
$11.78
$6.09

Technical Indicators

Market Signals
Indicator
SUNS
SCYX
Relative Strength Index (RSI) 42.04 38.72
Support Level $7.38 $0.67
Resistance Level $7.71 $5.56
Average True Range (ATR) 0.17 0.34
MACD -0.00 -0.12
Stochastic Oscillator 46.24 0.63

Price Performance

Historical Comparison
SUNS
SCYX

About SUNS Sunrise Realty Trust Inc.

Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS, and debt-like preferred equity securities across CRE asset classes and investment mix to include high-quality multi-family, condominiums, retail, office, hospitality, industrial, mixed-use, and specialty-use real estate. The company's portfolio is concentrated in the Southern U.S.

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

Share on Social Networks: